Physician profile
Daniel K Daniels
NPI 1174631352
$10,278.17
in general payments reported to CMS, 2019-2025
37 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,651 · 2020: $872 · 2021: $693 · 2022: $1,197 · 2023: $1,354 · 2024: $998 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,489.37 | 2019-2020 | |
| Abbvie INC. | $2,040.56 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $869.24 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $863.35 | 2019-2025 | Exalt Model D, General - Biliary Devices |
| Janssen Biotech, INC. | $505.73 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $485.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.14 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $332.10 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $314.27 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $246.91 | 2022-2025 | Ibsrela |
| Celgene Corporation | $239.99 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $177.23 | 2022-2023 | Rebyota |
| Braintree Laboratories, INC. | $145.47 | 2019-2023 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $136.77 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $133.33 | 2024-2025 | Omvoh |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $125.00 | 2025 | Rezdiffra |
| Qol Medical, LLC | $97.06 | 2022-2023 | Sucraid |
| Amgen INC. | $92.80 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $74.07 | 2024-2025 | Iqirvo |
| Enterra Medical, INC. | $61.58 | 2023 | |
| Olympus America INC. | $59.40 | 2019-2024 | Endoclot Phs |
| Ironwood Pharmaceuticals, INC | $53.27 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $51.02 | 2022-2024 | Dupixent |
| Ambu INC. | $46.09 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $31.90 | 2022 | |
| Shionogi INC | $31.43 | 2019 | |
| Exact Sciences Corporation | $31.12 | 2024 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $25.00 | 2024 | Terlivaz |
| Daiichi Sankyo INC. | $23.39 | 2022 | |
| Medtronic, INC. | $21.16 | 2023 | Interstim |
| Alnylam Pharmaceuticals INC. | $19.13 | 2021 | |
| Novo Nordisk INC | $19.13 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.76 | 2019 | |
| Shire North American Group INC | $17.84 | 2019 | |
| Sandoz INC. | $17.50 | 2023 | Hyrimoz |
| Merit Medical Systems INC | $16.05 | 2023 | Elation Balloon Dilator |
| Celltrion USA INC. | $15.33 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.